Omega-conotoxins act at presynaptic membranes, they bind and block voltage-gated calcium channels. This toxin inhibits neurotransmitter release, it blocks N-type calcium channels, probably a N-type (Cav2.2/CACNA1B) calcium channel variant. Expressed by the venom duct. The presence of a 'disulfide through disulfide knot' structurally defines this protein as a knottin. The cysteine framework is VI/VII (C-C-CC-C-C). Is under phase I clinical trial under the name AM336 by Amrad Corporation Limited for treating severe morphine-resistant pain stress. Belongs to the conotoxin O1 superfamily.